SEC Form 4 · accession 0001140361-15-014356
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A. Lewicki
Officer — EVP & Chief Scientific Officer
Period of report
Apr 1, 2015
Accepted (ET)
Apr 3, 2015 · 3:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Apr 1, 2015 | M | 8,500 | $1.43 | A | 29,785 | D | |
| Common StockF4,F2,F3 | Apr 1, 2015 | S | 8,500 | $25.1888 | D | 21,285 | D | |
| Common StockF2,F3 | Apr 2, 2015 | M | 8,500 | $1.43 | A | 29,785 | D | |
| Common StockF5,F2,F3 | Apr 2, 2015 | S | 6,940 | $25.2904 | D | 22,845 | D | |
| Common StockF6,F2,F3 | Apr 2, 2015 | S | 1,560 | $25.6979 | D | 21,285 | D | |
| Common StockF7 | holding | — | — | — | 83,530 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $1.43 | Apr 1, 2015 | M | 8,500 | A | — | Jan 11, 2017 | Common Stock | 8,500 | 31,777 | D |
| Stock Option (Right to Buy)F8 | $1.43 | Apr 2, 2015 | M | 8,500 | A | — | Jan 11, 2017 | Common Stock | 8,500 | 23,277 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2014.
- F2Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
- F3Includes 1,285 shares acquired under the Issuer's Employee Stock Purchase Plan on February 27, 2015.
- F4This transaction was executed in multiple trades in prices ranging from $24.63 to $25.56, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5This transaction was executed in multiple trades in prices ranging from $24.62 to $25.61, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6This transaction was executed in multiple trades in prices ranging from $25.62 to $26.12, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000.
- F8The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.